IMGN - ImmunoGen beats Q2 consensus August, 02 2019 07:10 AM ImmunoGen Inc. ImmunoGen (IMGN) Q2 results: Revenues: $15.5M (+66.7%); Non-cash royalty revenue: $10.4M (+44.4%); License and milestone fees: $5.1M ; R&D support: $0.05M (-87.5%).More news on: ImmunoGen, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...